Alpha-2-HS-glycoprotein (Ahsg or fetuin) was found to be downregulated in serum at both the pre-symptomatic and symptomatic stages; low serum alpha-2-HS-glycoprotein levels have been reported as indicative of a shorter survival time in GBM patients [69]. This evidence concerns the gene AHSG and glioblastoma.